Vertex Pharmaceuticals (VRTX) Analysts See $0.01 EPS; Van Kampen Municipal Opportunity Trust II (VOT) Sentiment Is 1.92

October 13, 2017 - By Clifton Ray

Analysts expect Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report $0.01 EPS on October, 24.They anticipate $0.10 EPS change or 111.11% from last quarter’s $-0.09 EPS. VRTX’s profit would be $2.52M giving it 3849.50 P/E if the $0.01 EPS is correct. After having $0.10 EPS previously, Vertex Pharmaceuticals Incorporated’s analysts see -90.00% EPS growth. The stock decreased 0.03% or $0.04 during the last trading session, reaching $153.98. About shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since October 13, 2016 and is uptrending. It has outperformed by 28.99% the S&P500.

Vanguard Mid-Cap Growth ETF is an exchange-traded share class of Vanguard Mid-Cap Growth Index Fund, which employs a passive management or indexing investment approach designed to track the performance of the MSCI US Mid Cap Growth Index (the Index). The ETF has market cap of $. The Index is a diversified index of growth stocks of medium-size United States companies. It currently has negative earnings. The Fund attempts to replicate the target Index by investing all, or substantially all, of its assets in the stocks that make up the Index, holding each stock in approximately the same proportion as its weighting in the Index.

Truepoint Inc. holds 11.26% of its portfolio in Vanguard Mid-Cap Growth ETF for 942,145 shares. Warren Averett Asset Management Llc owns 335,207 shares or 9.91% of their US portfolio. Moreover, Community Financial Services Group Llc has 3.65% invested in the company for 70,584 shares. The Michigan-based Cranbrook Wealth Management Llc has invested 3.38% in the stock. Nelson Van Denburg & Campbell Wealth Management Group Llc, a Nebraska-based fund reported 67,895 shares.

The ETF increased 0.17% or $0.21 on October 12, reaching $123.53. It is down 17.67% since October 13, 2016 and is uptrending. It has outperformed by 0.97% the S&P500.

Among 25 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 21 have Buy rating, 0 Sell and 4 Hold. Therefore 84% are positive. Vertex Pharmaceuticals had 71 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Wednesday, July 19 by Raymond James. Jefferies maintained the shares of VRTX in report on Wednesday, July 19 with “Buy” rating. The firm has “Hold” rating by H.C. Wainwright given on Wednesday, July 19. William Blair downgraded the stock to “Market Perform” rating in Tuesday, November 1 report. The firm has “Buy” rating given on Tuesday, December 1 by Stifel Nicolaus. The stock has “Market Outperform” rating by JMP Securities on Friday, March 17. The company was maintained on Friday, June 9 by Jefferies. Citigroup initiated it with “Buy” rating and $105 target in Wednesday, March 1 report. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Buy” rating given on Friday, June 23 by Needham. BMO Capital Markets maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday, September 25 with “Buy” rating.

Since April 28, 2017, it had 0 insider buys, and 16 sales for $52.08 million activity. ALTSHULER DAVID sold 7,500 shares worth $900,000. Shares for $1.09M were sold by Chodakewitz Jeffrey. On Thursday, June 1 the insider Silva Paul M sold $492,308. Arbuckle Stuart A sold $3.38M worth of stock or 28,320 shares. Shares for $12.22 million were sold by SMITH IAN F on Thursday, June 1. $151,045 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Bhatia Sangeeta N.. On Friday, June 2 the insider LEIDEN JEFFREY M sold $19.05 million.

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The company has market cap of $38.82 billion. The Firm is focused on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs in other indications. It has a 149.04 P/E ratio. The Company’s marketed medicines are ORKAMBI and KALYDECO.

Investors sentiment increased to 1.51 in 2017 Q2. Its up 0.20, from 1.31 in 2017Q1. It is positive, as 31 investors sold Vertex Pharmaceuticals Incorporated shares while 154 reduced holdings. 98 funds opened positions while 181 raised stakes. 231.33 million shares or 0.08% less from 231.51 million shares in 2017Q1 were reported. Tfs Ltd Liability holds 0.17% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 3,445 shares. C M Bidwell And Assocs Limited reported 10 shares. Dynamic Mgmt Ltd invested in 0.14% or 4,700 shares. Moreover, Atalanta Sosnoff Ltd has 1.31% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 288,084 shares. Financial Bank Of New York Mellon Corp accumulated 0.07% or 1.98 million shares. Pathstone Family Office Ltd Company reported 0% stake. Bp Public Ltd owns 0.15% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 31,000 shares. Moreover, Principal Fin Grp Inc has 0.05% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 379,838 shares. Greenwood Cap Assocs Limited Com owns 1,897 shares. Smith Asset Management Grp L P accumulated 191,080 shares. Endurance Wealth Management stated it has 0.11% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Cubist Systematic Strategies Limited reported 0.26% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Goldman Sachs Group Incorporated has invested 0.09% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Hanseatic Management Svcs invested in 4,934 shares. Rnc Mgmt Ltd Liability Corp has invested 0.03% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

By

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

>
Twitter Auto Publish Powered By : XYZScripts.com